Article

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair

2025-01-08

Abstract excerpt

Recent phase 3 clinical trial readouts have shown benefit of the combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors (ARPi) in metastatic, castration-resistant prostate cancer (mCRPC). While benefit was particularly evident in patients with tumours harbouring mutations in homologous recombination repair (HRR) genes, improved outcomes were also observed in pa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d91be617-90ea-5dc6-b7f2-85ab900430f0
DOI: 10.1101/2025.01.07.631700

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repairDOI 10.1101/2025.01.07.631700Read

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.Semantic proximity Read

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read

Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerSemantic proximity Read

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical DevelopmentSemantic proximity Read

Development of PARP inhibitors in advanced prostate cancerSemantic proximity Read

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patientsSemantic proximity Read

Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?Semantic proximity Read

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read